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activity at least three times a week. Obesity (OB) was deﬁ ned by a binary indicator if 
body mass index was greater than 30. The structural parameter, average treatment 
effect (ATE) was deﬁ ned as the impact of PA on obesity, if individuals are randomly 
assigned to PA. The second parameter average treatment in the treated (ATET) mea-
sured the impact of PA on obesity amongst those who became physically active, rather
than for the population as a whole. To control for the unobservable factors affecting 
PA, we speciﬁ ed a recursive bivariate probit model. To avoid identiﬁ cation based on
functional form, instruments added were presence of any limitations, and injury. 
Covariates included age, gender, race, ethnicity, geographical and metropolitan area 
location, smoking status, comorbidities and perceived physical and mental health.
RESULTS: Based on naïve probit model, the probability of obesity, evaluated at the 
means of the data, was 0.099 lower amongst those who were physically active (p 
0.001). Effect of selection bias was positive and signiﬁ cant (rho  0.55 p  0.001). 
Based on the recursive probit model, ATE was a 27.7% decrease (95% CI 0.279 to 
0.275) while ATET was a 38.8% decrease (95% CI 0.391 to 0.385) in probability
of obesity amongst those who were physically active. CONCLUSIONS: Unobservable 
heterogeneity may be masking the true effect of physical activity on obesity. Account-
ing for this bias conﬁ rms a signiﬁ cant protective effect of physical activity against the 
likelihood of obesity.
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OBJECTIVES: Patients with myelodysplastic syndrome (MDS) or severe anemia
requiring repeated transfusions of red blood cells (RBCs) risk developing transfusional
iron overload (TIO), which can cause organ damage and reduce survival. Iron chela-
tion therapy (ICT) has been shown to improve survival and quality of life in patients 
with TIO; however, ICT utilization in clinical practices is not well understood. 
METHODS: The medical records of patients diagnosed with MDS or severe anemia 
q6 months before data extraction, aged q 21 years at their diagnosis, received q1 RBC 
transfusion were reviewed. ICT-eligibility was deﬁ ned as q20 units of RBCs transfused 
or q2 serum ferritin (SF) tests q1000 mcg/L. Study endpoint was ICT-treatment rate 
among ICT-eligible patients with lower-risk MDS [IPSS (low or intermediate-1); WHO
(RA, RARS, RCMD, RCMD-RS or 5q); FAB (RA or RARS)]. Characteristics and
survival of treated and untreated groups were described. RESULTS: Medical records
data for 283 patients were extracted. Among 78 ICT-eligible patients with lower-risk 
MDS, only 32 (41%) received ICT. At ICT-initiation, treated patients received on 
average 13.3 transfusions (27.6 units) and mean ﬁ rst SF near-ICT-initiation was twice
the recommended level at 1949 mcg/L. Median overall survival for all ICT-eligible 
patients was signiﬁ cantly longer for those ICT-treated than untreated (8.7 versus 4.7 
years, log-rank p  0.02; multivariate hazards ratio  0.372, p  0.03). CONCLU-
SIONS: This observational study ﬁ nds only 41% of ICT-eligible patients with lower-
risk MDS received ICT in clinical practice, and their treatment was initiated later than 
recommended. Among all ICT-eligible patients, those who received ICT had a signiﬁ -
cantly better overall survival than untreated patients.
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OBJECTIVES: Oxycodone immediate release, alone or in combination (oxycodone), 
is widely used to treat pain. However, oxycodone is often associated with bothersome
side effects, which may lead to increased medical resource use, including prescription 
and over-the-counter (OTC) medications. The objective of this ﬁ rst analysis was to 
assess the frequency and bothersomeness of side effects and other medication use
among patients taking oxycodone. METHODS: An online survey was completed by
a nationwide convenience sample of patients currently taking oxycodone for non-
malignant pain. Detailed data on patient experience with oxycodone were collected. 
A minimum sample size of 600 was determined to ensure reasonably accurate esti-
mates around the frequency of side effects and medical resource utilization. RESULTS:
Among the 601 respondents [mean age of 45 years (range 18–86), 85.0% Caucasian,
69.1% female], almost half, 45.6%, were taking oxycodone for back/neck pain, 
16.8% for osteoarthritis/rheumatoid arthritis, 14.3% for pain due to injury/trauma, 
10.5% for recent surgery, 7.2% for ﬁ bromyalgia, and 5.7% for neuropathic pain. The
mean daily dose was 16.5 mg (range 2.5–200). Overall, 83.5% were bothered by side
effects with 29.9% being moderately/extremely bothered. Over half, 53.1%, were 
bothered by constipation, almost one-third, 31.3%, by nausea, 27.6% by pruritus, 
and 14.8% by vomiting, among others. A signiﬁ cantly higher proportion of respon-
dents bothered by side effects reported use of prescription (13.1% vs. 0%; p  0.001)
or OTC (20.5% vs. 9.1%; p  0.007) medications to manage those side effects, com-
pared to respondents not bothered by side effects. CONCLUSIONS: The majority of 
survey respondents experienced side effects of oxycodone, some of which led to the 
use of prescription and OTC medications. These results point to the potential beneﬁ ts, 
both humanistic and economic, of better-tolerated pain medications. Further analyses 
of this data will assess the health status, pain intensity, and other resource utilization
among oxycodone users.
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OBJECTIVES: Patients with primary immune deﬁ ciencies and many neurological
disorders are frequently treated with immune globulin, administered intravenously or 
subcutaneously. The aim of this study was to evaluate tolerability of intravenously 
administered immune globulin products in patients in the home setting. METHODS:
A retrospective, longitudinal cohort analysis of patients (18 years and older) provided 
intravenous immunoglobulin (IVIG) using data from the Accredo Therapeutics elec-
tronic medical record was conducted. Inclusion criterion was infusion of at least one 
dose of IVIG during the study period. Patients were followed from July 1, 2007 to 
June 28, 2008. Three components to estimate tolerability were evaluated. The ﬁ rst 
was aggregate adverse drug event rate. The second was infusion completion rate (ICR),
calculated by dividing the number of successful infusions by the number of attempted
infusions. The third measure was a managed therapy completion rate (MTCR-A) for 
patients that had an identiﬁ ed ADE and were still managed to completion of therapy.
RESULTS: The sample size for review was 33,065 doses of IVIG dispensed during the 
study period. The results based upon the three measures of tolerability were: 1) an 
ADE rate of 2.35% (95% CI: 1.79%–2.93%) based on 778 reported adverse drug
events; 2) an infusion completion rate (ICR) of 99.74% (95% CI: 99.65%–99.82%);
and 3) a managed through completion of therapy (MTCR-A) of 88.6% (95% CI: 
80.8%–92.35%). Gender, age, diagnoses and BMI were also evaluated for their effect
upon tolerability of infusion. CONCLUSIONS: Intravenous administration of immune
globulin is an important alternative infusion option for patients. Patients can be well 
managed in the home on intravenously administered immunoglobulin. These ﬁ ndings 
contribute to previous research related to safety of administration of immunoglobulin 
in the home.
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OBJECTIVES: The Diabetes Prevention Program (DPP) demonstrated that ILM 
improves lipid values, reduces blood pressure and reduces the risk of developing 
T2DM. Controversy over magnitude of whether these beneﬁ ts can be achieved cost-
effectively has diverted attention from questions about the generalizability of the
results. The high rate of treatment adherence in the DPP may not be reproducible in 
actual practice. The objective of this study was to assess the impact of treatment 
adherence to ILM on estimates of health beneﬁ ts and costs for a cohort of overweight
and obese patients at high risk of developing T2DM. METHODS: The IHE/JNJ
weight management model, a Markov-based, micro-simulation model that includes 
relevant co-morbidities and risk factors, was used to simulate the costs and health 
outcomes of ILM over 25 years for 500 cohorts of 1,000 hypothetical overweight and 
obese pre-T2DM patients. Efﬁ cacy and baseline population characteristics were taken 
primarily from the DPP. Costs for ILM and care associated micro- and macro-vascular 
complications and other co-morbidities as well as quality-of life data was obtained
from existing literature. Four scenarios were assessed: adherence as observed in the
DPP and reductions in the DPP adherence rate by 25%, 50%, and 75%. RESULTS:
In all, ILM resulted in 19.96 undiscounted life years (LYs), 18.03 undiscounted
quality-adjusted life years (QALYs), at a cost of $78,965, assuming DPP-like adher-
ence. Forty percent of the cohort ultimately developed T2DM. Reducing adherence 
by 25%, 50%, and 75% reduced LYs by 0.17, 0.29, and 0.40, QALYs by 0.36, 0.68, 
and 1.03, and increased costs by $2154, $4190, $6813, respectively. The rate of 
T2DM transition increased by 5, 10, and 15 percentage points, respectively. CON-
CLUSIONS: Patient adherence is an important driver of the beneﬁ ts and costs of ILM
and should be considered explicitly in cost-effectiveness estimates.
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OBJECTIVES: Neuropathic pain starts as or is caused by a primary lesion or dysfunc-
tion in the nervous system. It impacts use of health care resources and may incur
employment disruptions. The primary goal in managing neuropathic pain is to make 
it more tolerable. Three classes of atypical medications, anticonvulsants (ACs), sero-
